StocktoriaNeuroSense Therapeutics Ltd. NRSN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$11.1M | -$9.9M | -$12.0M |
| Net income | -$11.1M | -$10.2M | -$10.1M |
| Operating cash flow | -$7.7M | -$10.1M | -$8.4M |
| Free cash flow | -$7.7M | -$10.1M | -$8.4M |
| Total assets | $1.0M | $4.6M | $3.2M |
| Total liabilities | $2.6M | $2.0M | $4.9M |
| Shareholders' equity | -$1.6M | $2.6M | -$1.8M |
| Ratios | |||
| Return on assets | -1082.2% | -223.2% | -317.3% |
| Return on equity | 713.1% | -395.3% | 574.6% |
| Current ratio | 0.31 | 2.21 | 0.84 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001875091 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.